Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 190Thoracic 6Genitourinary 4Dermatologic 4Plasma cell 3Other hematologic neoplasm 3Breast 3Sarcoma 2Lymphoid 2Gynecologic 2CNS 2Myeloid 1Head & Neck 1Classical hematology 1

Conditions

Ovarian Neoplasms 16Peritoneal Neoplasms 14Colorectal Neoplasms 11Uterine Cervical Neoplasms 9Stomach Neoplasms 9Endometrial Neoplasms 8Neoplasm Metastasis 7Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Lung Neoplasms 4Fallopian Tube Neoplasms 4Esophageal Neoplasms 4Colonic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Rectal Neoplasms 3Mesothelioma 3HIV Infections 3Cholangiocarcinoma 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Acquired Immunodeficiency Syndrome 3Uterine Neoplasms 2Uterine Cervical Dysplasia 2Squamous Intraepithelial Lesions 2Pancreatic Neoplasms 2Neoplasms 2Melanoma 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2

Interventions

pembrolizumab 27Cyclophosphamide 14Gemcitabine 13fludarabine 11Carboplatin 10aldesleukin 9Trastuzumab 9Specimen Handling 9Nivolumab 9Magnetic Resonance Spectroscopy 8Biopsy 8olaparib 7Cisplatin 7Paclitaxel 6palbociclib 5atezolizumab 5Taxes 5Early Intervention, Educational 5Oxaliplatin 4Methods 4Irinotecan 4Drug Therapy 4Docetaxel 4Cetuximab 4Capecitabine 4Bevacizumab 4Albumin-Bound Paclitaxel 4talazoparib 3spartalizumab 3pertuzumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Fluorouracil × Gynecologic × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05733000 2023-03-10

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Northwestern University

Phase 2 Recruiting
94 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡